Mean cost of bringing new drug to US market Is $879.3 million
Jul 02, 2024
R&D has remained relatively stable among large pharma companies despite a 27.3% growth in sales.
Adjunctive IV argatroban, eptifibatide do not cut disability after stroke
By
Haymarket Media
Sep 06, 2024
The findings were seen among patients with acute ischemic stroke who were treated with intravenous thrombolysis within three hours after symptom onset.
Psychological resilience protects against earlier death in older adults
By
Haymarket Media
Sep 05, 2024
The findings were seen when adjusting for demographics, clinical factors and health-related behaviors.
Readmission varies with discharge setting for adult sepsis survivors
By
Haymarket Media
Sep 05, 2024
A high risk for 30-day readmission was seen with discharge to skilled nursing facilities, home health care and home.
Asthma inhalers tied to large greenhouse gas emissions production
By
Haymarket Media
Sep 04, 2024
Metered-dose inhalers were responsible for almost all inhaler-related emissions.
SGLT-2 inhibitors may cut dementia risk in patients with diabetes
By
Haymarket Media
Sep 03, 2024
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Recreational drug use tied to repeat cardiovascular events
By
Haymarket Media
Sep 03, 2024
The mean age of study participants was 63. The findings were seen for repeat events within one year of discharge from the intensive cardiac care unit.
Factory noise tied to higher blood pressure in workers
By
Haymarket Media
Aug 30, 2024
Higher odds were seen for long-term exposure to high decibels.
Fewer complications at 18 months seen with post-COVID-19 vaccination myocarditis
By
Haymarket Media
Aug 29, 2024
In contrast, post-COVID-19 myocarditis shows outcomes similar to conventional myocarditis.
Psilocybin has better response than placebo in antidepressant trials
By
Haymarket Media
Aug 28, 2024
Only high-dose psilocybin was better than placebo in antidepressant trials of escitalopram.